Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maureen M Okam

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Expert Review of Hematology|July 12, 2012
Novel approaches to the treatment of sickle cell disease: the potential of histone deacetylase inhibitorsMaureen M Okam, Benjamin L Ebert
Hematology/Oncology Clinics of North America|March 30, 2011
Anemia in pregnancyAlfred Ian Lee, Maureen M Okam
Haematologica|November 1, 2015
Iron deficiency anemia treatment response to oral iron therapy: a pooled analysis of five randomized controlled trialsMaureen M Okam, Todd A Koch, Minh-Ha Tran
The American Journal of Medicine|April 30, 2017
Iron Supplementation, Response in Iron-Deficiency Anemia: Analysis of Five TrialsMaureen M Okam, Todd A Koch, Minh-Ha Tran
American Journal of Hematology|September 12, 2012
Comparative rates of adverse events with different formulations of intravenous ironMaureen M Okam, Elyse Mandell, Nathanael Hevelone, et al.
Medical Care|June 14, 2014
National trends in hospitalizations for sickle cell disease in the United States following the FDA approval of hydroxyurea, 1998-2008Maureen M Okam, Shimon Shaykevich, Benjamin L Ebert, et al.
Blood|June 6, 2015
Phase 1/2 trial of vorinostat in patients with sickle cell disease who have not benefitted from hydroxyureaMaureen M Okam, Erica B Esrick, Elyse Mandell, et al.
Blood|February 5, 2013
Sickle cell vaso-occlusion causes activation of iNKT cells that is decreased by the adenosine A2A receptor agonist regadenosonJoshua J Field, Gene Lin, Maureen M Okam, et al.
JAMA|March 3, 2011
Nitric oxide for inhalation in the acute treatment of sickle cell pain crisis: a randomized controlled trialMark T Gladwin, Gregory J Kato, Debra Weiner, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Expert Review of Hematology|July 12, 2012
Novel approaches to the treatment of sickle cell disease: the potential of histone deacetylase inhibitorsMaureen M Okam, Benjamin L Ebert
Hematology/Oncology Clinics of North America|March 30, 2011
Anemia in pregnancyAlfred Ian Lee, Maureen M Okam
Haematologica|November 1, 2015
Iron deficiency anemia treatment response to oral iron therapy: a pooled analysis of five randomized controlled trialsMaureen M Okam, Todd A Koch, Minh-Ha Tran
The American Journal of Medicine|April 30, 2017
Iron Supplementation, Response in Iron-Deficiency Anemia: Analysis of Five TrialsMaureen M Okam, Todd A Koch, Minh-Ha Tran
American Journal of Hematology|September 12, 2012
Comparative rates of adverse events with different formulations of intravenous ironMaureen M Okam, Elyse Mandell, Nathanael Hevelone, et al.
Medical Care|June 14, 2014
National trends in hospitalizations for sickle cell disease in the United States following the FDA approval of hydroxyurea, 1998-2008Maureen M Okam, Shimon Shaykevich, Benjamin L Ebert, et al.
Blood|June 6, 2015
Phase 1/2 trial of vorinostat in patients with sickle cell disease who have not benefitted from hydroxyureaMaureen M Okam, Erica B Esrick, Elyse Mandell, et al.
Blood|February 5, 2013
Sickle cell vaso-occlusion causes activation of iNKT cells that is decreased by the adenosine A2A receptor agonist regadenosonJoshua J Field, Gene Lin, Maureen M Okam, et al.
JAMA|March 3, 2011
Nitric oxide for inhalation in the acute treatment of sickle cell pain crisis: a randomized controlled trialMark T Gladwin, Gregory J Kato, Debra Weiner, et al.
Pageof 1